<p class="MsoNormal">Rating Agency Moody's Investors Service said on Sunday that the authorization of Pfizer and BioNTech's vaccine for COVID-19 in the US is considered positive for Pfizer’s credit profile, with no impact on the company’s A2/Prime-1 ratings or the stable outlook. </p><p class="MsoNormal"></p>
